Investors Are in Love With Dendreon Corporation

Despite a lackluster quarter where it trailed rivals Johnson & Johnson and Medication, investors sent sales of Dendreon up 15%.

Mar 3, 2014 at 7:58PM

Dendreon (NASDAQ:DNDN) ended up 15% today.

I have no idea why. There didn't seem to be anything in today's press releases nor on the conference call that justified that kind of move.

Let's take a few quotes that John Johnson, Dendreon's chairman, president, and CEO, laid out in the press release that sound positive.

Profitability remains our key goal, and we successfully reduced our costs of goods sold on a pro forma basis to 51% in the fourth quarter.

Provenge

Source: Dendreon

Dendreon's prostate cancer therapy, Provenge, is expensive to make since it has to be tailor made from each patient's immune cells. While spending 51% of the sales price to make the drug is better than the 69% it spent in the third quarter, but it's still 51%! Unless you've got serious volume -- Dendreon doesn't -- it's hard to make money selling a drug with that low of a profit margin.

Automation should help Dendreon get the costs even lower, but management wasn't willing to give a timeframe given the need to get the Food and Drug Administration to sign off on the manufacturing changes.

We expect our first quarter 2014 revenues to be consistent with our first quarter 2013 results.

Flat year-over-year sales certainly sounds better than last quarter when sales fell from $85.4 million in the fourth quarter of 2012 to $74.8 million in the fourth quarter of last year, but when you go back and look at the first quarter 2013 results, you'll see sales were only $67.6 million. So Dendreon is forecasting a quarter-over-quarter decline of 9.6%. The decrease in volume will cause cost of goods sold to go in the wrong direction.

Provengetreatment

Source: Dendreon

In theory, there should be some seasonality to sales. Patients are less likely to see their doctor over the holiday, so they're less likely to get signed up to be infused with Provenge in the first quarter. But that kind of decline would be a minor blip for a drug with robust sales growth.

Provenge's competitors in the prostate cancer space -- Johnson & Johnson's (NYSE:JNJ) Zytiga and Xtandi, sold by Astellas and Medivation (NASDAQ:MDVN) -- are clearly dampening any growth.

Actually, that's putting it nicely. They're kicking Provenge's butt. Johnson & Johnson sold $211 million worth of Zytiga in the U.S. in the fourth quarter and Medivation registered $126 million in U.S. sales for Xtandi for the same time period. Keep in mind both have been on the market for less time that Provenge.

We are focused on becoming cash flow breakeven as soon as possible.

Been there. Done that.

We are also making progress with regard to global expansion and will be making Provenge commercially available in Europe.

The European Commission approved Provenge last September, so it's not really news that Dendreon is moving forward with selling the drug across the pond. It doesn't expect to treat the first European patients until the fourth quarter.

It's not clear whether selling the drug in Europe will help Dendreon get to profitability. Drugs in Europe typically sell for a 20% to 25% less than they do stateside. Dendreon is using a contract manufacturer to manufacture Provenge. With automation already set up, cost of goods sold should be less than it is in the U.S., but Dendreon wasn't willing to tell investors what it'll be paying its contractor to make the treatment.

What wasn't said should concern investors
From Johnson on the conference call:

On our third quarter call, we indicated that we would provide an update regarding our convertible debt. Over the last quarter, we have spent considerable time exploring our options with our advisors and have made significant progress in our thinking. As you would expect, we are not going to provide details at this point in time, except to say that addressing our convertible debt remains a top priority and we are well advised.

Dendreon has to deal with its debt situation. It has $559 million in senior notes due in 2016 and another $28 million due this year. To put it bluntly, if Dendreon can't restructure that debt, it's going to go bankrupt. With a market cap of less than that debt, it's not like the company can just sell shares to raise the cash.

It's great that the company is "well advised," but it would be nice for the company to live up to its guidance and let investors know their plan.

No slow growth here: our top pick for 2014
Unlike Dendreon, the top pick of The Motley Fool's chief investment officer has serious potential. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers